Allergan completes acquisition of Chase Pharmaceuticals

Industry:    2016-11-24

Allergan Plc

* Allergan acquires Chase Pharmaceuticals to expand CNS research and development pipeline and build on commitment to Alzheimer’s disease

* Deal for an upfront payment of $125 million

* Allergan to advance CPC-201 into Phase 3 registration study in 2017

* Deal includes additional potential milestone payments related to chase’s lead compound, CPC-201, and certain backup compounds

* Allergan plc – Allergan to advance cpc-201 into phase 3 registration study in 2017 Source text for Eikon: Further company coverage:

 

Recent Articles on M&A

Open-Delisting-Offer

Whether Global corporation should combine mandatory Open Offer and Delisting Offer?

Apollo-Hospitals-Slump-Sale-Retail-Pharmacy

Apollo Hospitals spins off its Retail Pharmacy business

Exit-Minority-Shareholders-Companies-Act-Provisions

Know which Sections of the Companies Act gives Exit to Minority Shareholders

Scheme-Merger-Approved-Objection-RD

Scheme of Merger Approved – Despite Objections from Regional Director 

print
Source: